What we are finding is that a lot of these companies are not doing the manufacturing, and so it is a very new and interesting business model, and I am convinced that it is one that is really negative for patients, providers, hospitals, and for Federal and State health care programs.
Expressing concerns about the negative effects of new pharmaceutical business models on healthcare.
Share & report
More from Susan Collins
I will not support a cut in PEPFAR, which is a program that has saved literally millions of lives and has been extremely effective and well-run.
We got two of our bills approved today, one unanimously and one with only one dissenting vote. Had the issue of the FBI building not come up, we would have had a third bill with strong bipartisan support.
As the senator representing … the oldest state in the nation, this is a particular concern.
Other voices in this conversation
